Mylan has entered into an exclusive global collaboration agreement with Momenta Pharmaceuticals to develop, manufacture and commercialize six of Momenta’s biosimilar candidates, including abatacept (Bristol-Myers Squibb’s rheumatoid arthritis drug ORENCIA), which had $1.7 billion in sales in 2014. Momenta will receive $45 million up front and as much as $200 million in milestone-related payments, with each company sharing the costs and profits for the products. The companies will...